HALO Earnings Prediction
The chart below shows how HALO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HALO sees a +0.94% change in stock price 10 days leading up to the earnings, and a +7.77% change 10 days following the report. On the earnings day itself, the stock moves by +0.10%. This data can give you a slight idea of what to expect for the next quarter's release.
HALO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
298.01M
29.55%
2.73%
Gross Margin
79.93%
14.94%
4.02%
Operating Margin
58.89%
34.08%
4.67%
Net Margin
45.98%
23.87%
-2.65%
EPS
1.06
63.08%
0.95%
No Data Available
HALO Earnings Analysis
Halozyme Therapeutics Inc Corporation (HALO.O) Earnings Conference Call
Positive
Record Revenue Milestone: Halozyme Therapeutics, Inc. reported a record-breaking total revenue exceeding $1 billion for the first time, growing 22% over the prior year.
Financial Guidance Upgrade: The company raised its financial guidance twice during the year, exceeding expectations for royalty revenue, adjusted EBITDA, and non-GAAP EPS.
Patient Safety Database Expansion: Halozyme estimates that 1 million patients have received drugs delivered subcutaneously with ENHANZE, establishing a strong safety database.
ENHANZE Product Approvals: Four major products or new indications with ENHANZE received approval in a major region, adding future growth opportunities.
Patent Protection Extension: The patent protection of ENHANZE in Europe was extended to 2029, maintaining royalty rates for key products.
Royalty Revenue Surge: Royalty revenue grew by 27% in 2024, totaling $571 million, which was a key driver for total revenues exceeding $1 billion.
Net Income Surge: Net income increased by 58% year-over-year to $444 million, reflecting strong financial performance.
Projected Revenue Growth: The company projects total revenue growth of 13% to 21% for 2025, driven by DARZALEX subcutaneous, Phesgo, and VYVGART Hytrulo.
DARZALEX Sales Surge: Johnson & Johnson reported that DARZALEX sales grew almost 24% in Q4 2024, with subcutaneous formulations representing 95% of total sales in the U.S.
Phesgo Revenue Surge: Roche's Phesgo grew to CHF500 million in Q4 2024, representing a 72% year-over-year increase, with expectations for continued growth.
Quarterly Sales Achievement: VYVGART Hytrulo with ENHANZE achieved fourth quarter sales of $737 million, driven by adoption in generalized myasthenia gravis.
Strong Financial Health: Halozyme's strong balance sheet showed cash and equivalents of $596 million, up from $336 million the previous year, indicating solid financial health.
Royalty Revenue Projections: The company expects to exceed $1 billion in royalty revenue by 2027, driven by continued growth of DARZALEX and Phesgo.
Development Agreement Innovation: Halozyme has signed a development agreement for a small-volume auto-injector with a current partner, indicating ongoing innovation and collaboration.
Negative
Revenue Growth Slowdown: Despite beating earnings expectations, Halozyme's revenue growth is projected to slow down in the first quarter of 2025, with a decrease of approximately 10% in royalty revenue compared to the fourth quarter of 2024 due to annual contractual rate resets.
Revenue Decline Anticipation: The company anticipates total revenues to decrease sequentially from the fourth quarter of 2024 to the first quarter of 2025, as no milestones are planned in the first quarter and product sales are expected to be weighted in the second half of 2025.
Net Debt Concerns: Halozyme's net debt position is $929 million, which could raise concerns about financial leverage and the company's ability to manage its debt obligations effectively.
FDA Response Impact: The company has faced a complete response letter from the FDA regarding the subcutaneous formulation of Amivantamab, which could delay its market entry and revenue generation potential.
Future Revenue Projections: While there are strong projections for future revenue growth, the company has not yet secured new deals or nominations for ENHANZE, which could impact long-term growth prospects.
HALO FAQs
How does HALO typically perform around its earnings report dates?
Is Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
HALO Earning Call Sentiment
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript
HALO.O
0.28%Positive
The earnings call shows strong financial performance with record revenue, significant EPS growth, and an optimistic outlook. The Q&A section reveals confidence in future partnerships and revenue streams, though some uncertainties remain. The ASR plan and strong financial metrics suggest a positive stock reaction.
